Actively Recruiting
EEG-based Neurofeedback to Improve Emotion Regulation in Major Depressive Disorder: A Randomized Clinical Trial
Led by Corporacion Parc Tauli · Updated on 2025-06-27
72
Participants Needed
1
Research Sites
67 weeks
Total Duration
On this page
Sponsors
C
Corporacion Parc Tauli
Lead Sponsor
H
Horizon 2020 - European Commission
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate whether EEG-based neurofeedback targeting the emotion regulation network through swLORETA can improve emotional regulation and reduce symptoms in adults with Major Depressive Disorder (MDD) who have not responded sufficiently to first-line treatments. The main questions it aims to answer are: * Does EEG-neurofeedback improve emotional self-regulation and reduce clinical symptoms in patients with MDD with or without anxiety symptoms? * Are changes in EEG resting-state activity and stress biomarkers (e.g., cortisol) associated with clinical improvement? Researchers will compare an active neurofeedback group, a sham (placebo) neurofeedback group, and a treatment-as-usual control group to see if real-time EEG-neurofeedback leads to greater improvement in mood, emotional regulation, and neurophysiological indicators than placebo or no additional intervention. Participants will: * Receive 10 sessions of either real or sham EEG-neurofeedback (or no sessions in the control group) over 5 weeks. * Complete clinical, psychological, and neurophysiological assessments before (week 0) and after the intervention (week 6). * Provide repeated saliva samples to assess stress-related biomarkers at week 0 and week 6. * Continue their standard pharmacological treatment throughout the study.
CONDITIONS
Official Title
EEG-based Neurofeedback to Improve Emotion Regulation in Major Depressive Disorder: A Randomized Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A primary diagnosis of Major Depressive Disorder (MDD), established by qualified psychiatrists according to DSM-5 criteria.
- Patients with comorbid anxiety or anxiety symptoms will be included, provided that MDD is the primary diagnosis.
- Participants must score at least 20 on the Montgomery-�C5sberg Depression Rating Scale (MADRS), indicating a moderate level of depression.
- All participants must be on a stable psychopharmacological treatment for at least 6 weeks before beginning of the study.
You will not qualify if you...
- Patients with a concurrent diagnosis of MDD and other severe psychiatric disorders.
- Patients with serious physical illnesses that could interfere with study participation or the interpretation of results.
- Participants currently undergoing structured psychotherapy or other interventions unrelated to standard psychopharmacological treatment.
- Patients presenting with active suicidal ideation, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS), at the time of screening will not be eligible due to associated risks.
- Active substance abuse or dependence (except nicotine).
- Intellectual disability or conditions that interfere with the ability to provide informed consent and complete the intervention (e.g., severe visual or hearing impairments).
- Pregnancy.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, Cataluña, Spain, 08208
Actively Recruiting
Research Team
V
Virginia Soria, MD,PhD
CONTACT
D
Diego Palao, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here